换一批
换一批Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
作者：
Rachel M,Hurley [1]
;
Cordelia D,McGehee [1]
;
Ksenija,Nesic [2]
;
Cristina,Correia [1]
;
Taylor M,Weiskittel [1]
;
Rebecca L,Kelly [1]
;
Annapoorna,Venkatachalam [1]
;
Xiaonan,Hou [3]
;
Nicholas M,Pathoulas [4]
;
X Wei,Meng [1]
;
Olga,Kondrashova [2]
;
Marc R,Radke [5]
;
Paula A,Schneider [4]
;
Karen S,Flatten [4]
;
Kevin L,Peterson [4]
;
Marc A,Becker [3]
;
Ee Ming,Wong [6]
;
Melissa S,Southey [6]
;
Alexander,Dobrovic [7]
;
Kevin K,Lin [8]
;
Thomas C,Harding [8]
;
Iain,McNeish [9]
;
Christian A,Ross [10]
;
Jill M,Wagner [3]
;
Matthew J,Wakefield [2]
;
Clare L,Scott [2]
;
Paul,Haluska [3]
;
Andrea E,Wahner Hendrickson [3]
;
Larry M,Karnitz [1]
;
Elizabeth M,Swisher [5]
;
Hu,Li [1]
;
S John,Weroha [3]
;
Scott H,Kaufmann [1]
作者单位：
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
[1]
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
[2]
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
[3]
Division of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
[4]
Department of Obstetrics & Gynecology, University of Washington, Seattle, WA 98195, USA.
[5]
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria 3800, Australia.
[6]
University of Melbourne Department of Surgery, Austin Hospital, Heidelberg, Victoria 3084, Australia.
[7]
Clovis Oncology, San Francisco, CA 94158, USA.
[8]
Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, W12 0NN United Kingdom.
[9]
Division of Information Technology, Mayo Clinic, Rochester, MN 55905, USA.
[10]
DOI
10.1093/narcan/zcab028
PMID
34316715
发布时间
2021-12-24
- 浏览0
NAR cancer
NAR cancer
2021年3卷3期
zcab028页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
